Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Acute Schizophrenia · Schizophrenia · RVPH

REVIVA PHARMACEUTICALS HOLDINGS

REVIVA PHARMACEUTICALS HOLDINGS, INC.

REVIVA PHARMACEUTICALS HOLDINGS patent portfolio — 28 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
Cupertino, USA HQ
20 Employees
Public company Type
RVPH · NYSE Ticker
Company details
Status
Public
HQ
Cupertino, USA
Employees
20
Programs
3
Drugs
1
Patents
28
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

REVIVA PHARMACEUTICALS HOLDINGS patents

28 pharmaceutical patents indexed for REVIVA PHARMACEUTICALS HOLDINGS. 0 expire within 24 months.

REVIVA PHARMACEUTICALS HOLDINGS has 28 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

28 patents

Patent portfolio

  1. US 12053477

    Methods for treating pulmonary fibrosis

    Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10441590

    Methods for treating pulmonary hypertension

    Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10035761

    Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives

    Expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9975862

    Arylpiperazine derivatives and methods of utilizing same

    Expires Mon May 17 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9907803

    Methods for treating attention deficit hyperactivity disorder

    Expires Mon Mar 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9695116

    Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives

    Expires Mon Jun 29 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9604944

    Arylpiperazine derivatives and methods of utilizing same

    Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9302981

    Synthesis, methods of using, and compositions of cycloalkylmethylamines

    Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9296681

    Cycloalkylmethylamines

    Expires Mon Mar 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9255076

    Arylpiperazine derivatives and methods of utilizing same

    Expires Mon Feb 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9238625

    Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives

    Expires Mon Jan 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9096515

    Methods of using cycloalkylmethylamine derivatives

    Expires Mon Jul 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8980883

    Arylpiperazine derivatives and methods of utilizing same

    Expires Mon Mar 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8859552

    Methods of utilizing arylpiperazine derivatives

    Expires Mon Oct 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8669285

    Synthesis, methods of using, and compositions of cycloalkylmethylamines

    Expires Mon Mar 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8604244

    Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives

    Expires Mon Dec 05 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8580822

    Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors

    Expires Mon Nov 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8575185

    Compositions, synthesis, and methods of utilizing quinazolinedione derivatives

    Expires Mon Oct 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8461154

    Methods of utilizing arylpiperazine derivatives

    Expires Mon Jun 06 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8445714

    Cycloalkylmethylamines

    Expires Mon May 16 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8431570

    Methods of utilizing arylpiperazine derivatives

    Expires Mon Apr 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8372883

    Methods of using cycloalkylmethylamines

    Expires Mon Feb 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8338632

    Cycloalkylmethylamines

    Expires Mon Dec 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8247563

    Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors

    Expires Mon Aug 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8247420

    Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents

    Expires Mon Aug 16 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8207163

    Compositions, synthesis, and methods of using piperazine based antipsychotic agents

    Expires Mon Jun 21 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8188076

    Compositions, synthesis, and methods of utilizing arylpiperazine derivatives

    Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 7989500

    Synthesis, methods of using, and compositions of cycloalkylmethylamines

    Expires Mon Jul 28 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does REVIVA PHARMACEUTICALS HOLDINGS have?

28 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do REVIVA PHARMACEUTICALS HOLDINGS patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.